CN103826634A - 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮在治疗中度肝损伤患者癌症中的应用 - Google Patents
4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮在治疗中度肝损伤患者癌症中的应用 Download PDFInfo
- Publication number
- CN103826634A CN103826634A CN201280044613.4A CN201280044613A CN103826634A CN 103826634 A CN103826634 A CN 103826634A CN 201280044613 A CN201280044613 A CN 201280044613A CN 103826634 A CN103826634 A CN 103826634A
- Authority
- CN
- China
- Prior art keywords
- patient
- amino
- patients
- treatment
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535142P | 2011-09-15 | 2011-09-15 | |
| US61/535,142 | 2011-09-15 | ||
| PCT/US2012/054046 WO2013039764A1 (en) | 2011-09-15 | 2012-09-07 | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103826634A true CN103826634A (zh) | 2014-05-28 |
Family
ID=46846036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280044613.4A Pending CN103826634A (zh) | 2011-09-15 | 2012-09-07 | 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮在治疗中度肝损伤患者癌症中的应用 |
Country Status (12)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| EP3093014A1 (en) * | 2015-05-13 | 2016-11-16 | Aventis Pharma S.A. | Cabazitaxel and its use for treating cancer |
| AU2020345791A1 (en) * | 2019-09-11 | 2022-03-31 | Inspirna, Inc. | Methods of treating cancer |
| JP7689964B2 (ja) | 2019-12-13 | 2025-06-09 | インスピルナ,インコーポレーテッド | 金属塩及びその使用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004105763A2 (en) * | 2003-05-27 | 2004-12-09 | Haegerkvist Robert Per | Use of tyrosine kinase inhibitor to treat diabetes |
| CN1711088A (zh) * | 2002-11-13 | 2005-12-21 | 希龙公司 | 治疗癌症的方法及相关方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0113757B8 (pt) | 2000-09-11 | 2017-11-07 | Chiron Corp | derivados de quinolinona como inibidores de tirosina quinase |
| EP2573079A3 (en) | 2002-08-23 | 2015-03-11 | Novartis AG | Benzimidazole quinolinones and uses thereof |
| SG148864A1 (en) * | 2002-11-13 | 2009-01-29 | Chiron Corp | Methods of treating cancer and related methods |
| EP2270000B1 (en) | 2005-05-23 | 2015-07-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
| AR070924A1 (es) | 2008-03-19 | 2010-05-12 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona |
| BR112012012210B8 (pt) * | 2009-11-23 | 2021-05-25 | Cerulean Pharma Inc | conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano |
-
2012
- 2012-09-07 JP JP2014530703A patent/JP2014526506A/ja active Pending
- 2012-09-07 EP EP12758976.0A patent/EP2755655A1/en not_active Withdrawn
- 2012-09-07 IN IN2060DEN2014 patent/IN2014DN02060A/en unknown
- 2012-09-07 WO PCT/US2012/054046 patent/WO2013039764A1/en not_active Ceased
- 2012-09-07 MX MX2014003182A patent/MX2014003182A/es not_active Application Discontinuation
- 2012-09-07 CN CN201280044613.4A patent/CN103826634A/zh active Pending
- 2012-09-07 BR BR112014005653A patent/BR112014005653A2/pt not_active IP Right Cessation
- 2012-09-07 KR KR1020147006625A patent/KR20140062485A/ko not_active Withdrawn
- 2012-09-07 CA CA2848210A patent/CA2848210A1/en not_active Abandoned
- 2012-09-07 US US14/342,612 patent/US20140221389A1/en not_active Abandoned
- 2012-09-07 RU RU2014114827/15A patent/RU2014114827A/ru not_active Application Discontinuation
- 2012-09-07 AU AU2012308993A patent/AU2012308993A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1711088A (zh) * | 2002-11-13 | 2005-12-21 | 希龙公司 | 治疗癌症的方法及相关方法 |
| WO2004105763A2 (en) * | 2003-05-27 | 2004-12-09 | Haegerkvist Robert Per | Use of tyrosine kinase inhibitor to treat diabetes |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014526506A (ja) | 2014-10-06 |
| WO2013039764A1 (en) | 2013-03-21 |
| EP2755655A1 (en) | 2014-07-23 |
| BR112014005653A2 (pt) | 2017-03-28 |
| CA2848210A1 (en) | 2013-03-21 |
| RU2014114827A (ru) | 2015-10-20 |
| IN2014DN02060A (cg-RX-API-DMAC7.html) | 2015-05-15 |
| US20140221389A1 (en) | 2014-08-07 |
| AU2012308993A1 (en) | 2014-03-27 |
| KR20140062485A (ko) | 2014-05-23 |
| MX2014003182A (es) | 2014-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tran et al. | Langerhans cell histiocytosis: a neoplastic disorder driven by Ras-ERK pathway mutations | |
| Li et al. | Nicotinamide benefits both mothers and pups in two contrasting mouse models of preeclampsia | |
| Judson et al. | A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug | |
| Galvin et al. | Neurofibromatosis in the era of precision medicine: development of MEK inhibitors and recent successes with selumetinib | |
| Rajakariar et al. | Post transplant T‐cell lymphoma: a case series of four patients from a single unit and review of the literature | |
| Benadiba et al. | Growth inhibitory effects of the Diruthenium-Ibuprofen compound,[Ru2Cl (Ibp) 4], in human glioma cells in vitro and in the rat C6 orthotopic glioma in vivo | |
| Zhang et al. | Silibinin efficacy in a rat model of pulmonary arterial hypertension using monocrotaline and chronic hypoxia | |
| Duncan et al. | 18F-FDG-PET/CT imaging in an IL-6-and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib | |
| Ohkubo et al. | Possible case of polyarteritis nodosa with epididymitis following COVID-19 vaccination: a case report and review of the literature | |
| He et al. | Expression of LDH and CEA in serum in the process of targeted therapy of lung adenocarcinoma and the association between them and prognosis | |
| Yamamoto et al. | Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement–positive non–small cell lung cancer treated with alectinib | |
| Markovic et al. | Phase II trial of KW2189 in patients with advanced malignant melanoma | |
| US20140221389A1 (en) | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients | |
| CN113694205B (zh) | 5-ht受体抑制剂和顺铂在制备治疗肝癌的药物中的应用 | |
| Turcotte et al. | Toxicology evaluation of radiotracer doses of 3'-deoxy-3'-[18F] fluorothymidine (18F-FLT) for human PET imaging: Laboratory analysis of serial blood samples and comparison to previously investigated therapeutic FLT doses | |
| US20210379095A1 (en) | Methods and Combination Therapy to Treat Biliary Tract Cancer | |
| Shafie et al. | Burkitt lymphoma presenting as cecum mass and spontaneous tumor lysis syndrome with hypercalcemia | |
| Friday et al. | A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors | |
| Nirojini et al. | Therapeutic drug monitoring of 5-fluorouracil in head and neck cancer patients: an interventional pilot study | |
| Viertl et al. | Increase of [18F] FLT tumor uptake in vivo mediated by FdUrd: toward improving cell proliferation positron emission tomography | |
| US20200268703A1 (en) | Medicine for treating advanced or recurrent cancer patient being non-responsive or non-tolerant to standard chemotherapy and incurable and unresectable | |
| Shiraishi et al. | A Case Report on Pericardial Effusion Associated With Selpercatinib in the First Patient With Rearranged During Transfection (RET) Fusion-Positive Lung Cancer | |
| US20250017931A1 (en) | Methods of personalizing cancer treatment | |
| Sarkaria et al. | NCCTG Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in newly diagnosed glioblastoma multiforme patients | |
| CN120983433A (zh) | 一种抑制仑伐替尼耐药性的药物组合物及其在肝癌中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140528 |